Company PharmAbcine Inc.

Equities

A208340

KR7208340000

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Bio Therapeutic Drugs

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-01-18 pm EST			5-day change	1st Jan Change
2,915 ^KRW	-8.91%		-.--%	-22.27%

Jan. 24	PharmAbcine Inc. Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA®? (Pembrolizumab) in Patients with Advanced or Metastatic Solid Tumors	CI
2023	PharmAbcine Inc. announced that it has received KRW 5.000000492 billion in funding	CI

PharmAbcine Inc. is a Korea-based company mainly engaged in the research and development of biopharmaceuticals. The Company researching and developing antibody therapeutics to provide patients with the antibodies needed to cure the disease. The Companyâs major products include tanibirumab used for cancer treatment, among others. The Company also carries out technology transfer about its pipelines with domestic and overseas pharmaceutical companies.

Number of employees: 44

KRW in Million	2022	Weight	2023	Weight	Delta
Bio-anticancer Drug 100.0 %	207	100.0 %	75	100.0 %	-63.72%

KRW in Million	2022	Weight	2023	Weight	Delta
South Korea 100.0 %	207	100.0 %	75	100.0 %	-63.72%

Managers	Title	Age	Since
Jin-San Yoo FOU	Founder	61	08-08-31
Chul-Bum Kim DFI	Director of Finance/CFO	59	-
Hyun-Seon Park COO	Chief Operating Officer	61	18-12-31
Won-Sub Lee CTO	Chief Tech/Sci/R&D Officer	55	07-12-31
Joon-Hee Choi BRD	Director/Board Member	60	-
Du-Yeong Jeong AUD	Comptroller/Controller/Auditor	65	-

Members of the board	Title	Age	Since
Chul-Bum Kim DFI	Director of Finance/CFO	59	-
Jin-San Yoo FOU	Founder	61	08-08-31
Won-Sub Lee CTO	Chief Tech/Sci/R&D Officer	55	07-12-31
Dong-Sub Lee BRD	Director/Board Member	60	-
Joon-Hee Choi BRD	Director/Board Member	60	-
Hyeon-Seo Koo BRD	Director/Board Member	58	-
Hyun-Seon Park COO	Chief Operating Officer	61	18-12-31
Hang-Rae Kim BRD	Director/Board Member	51	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	30,201,108	29,755,191 ( 98.52 %)	8,663 ( 0.0287 %)	98.52 %

Name	Equities	%	Valuation
San Yoo Jin 4.444 %	1,342,093	4.444 %	3 M ₩
Tire Bank Co., Ltd. 3.535 %	1,067,718	3.535 %	2 M ₩
Seongyeon Kim 2.295 %	693,087	2.295 %	2 M ₩
Jeong-gyu Kim 1.863 %	562,697	1.863 %	1 M ₩
Soo-yeon Kim 1.331 %	401,930	1.331 %	875 002 ₩
Jin-San Yoo 0.9316 %	281,351	0.9316 %	612 501 ₩
Yukon Partners Co. Ltd. 0.3394 %	102,505	0.3394 %	223 153 ₩
Sung-Hwan An 0.2662 %	80,386	0.2662 %	175 000 ₩
Jeong-gil Seo 0.2662 %	80,386	0.2662 %	175 000 ₩
Yong-ju Kim 0.2662 %	80,386	0.2662 %	175 000 ₩

PharmAbcine Inc.

70 Yuseong-daero 1689 beon-gil Yuseong-gu

34047, Daejeon

http://www.pharmabcine.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
PHARMABCINE INC.	-22.27%	65.04M
VERTEX PHARMACEUTICALS INCORPORATED	+9.97%	115B
REGENERON PHARMACEUTICALS, INC.	+11.95%	106B
ARGENX SE	-2.59%	21.96B
BIONTECH SE	-12.41%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-4.03%	18.08B
WUXI APPTEC CO., LTD.	-38.57%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.12%	14.32B
SAREPTA THERAPEUTICS, INC.	+35.08%	12.42B

Bio Therapeutic Drugs